Deals18 Jun 2025, 01:33 pm
Welcure Drugs & Pharmaceuticals Ltd Executes Rs. 517 Crores Global Sourcing Mandate
AI Summary
Welcure Drugs & Pharmaceuticals Ltd has executed a definitive mandate for third-party sourcing and procurement services aggregating ~¥517 crore with an overseas client, Fortune Sagar Impex Company Limited, Thailand. The mandate is a fee-based sourcing & procurement of multiple finished-dosage SKUs (Ex-Works model) with Welcure's fixed 5 % commission on cost of goods. The estimated service income revenue stream is ~%25.85 crore to be recognized over FY 2025-26. The execution is on a call-off basis, with the initial lot targeted immediately upon fulfilment of the customary prefunding milestones and the balance tranches expected to conclude by 30 September 2026.
Key Highlights
- Welcure Drugs & Pharmaceuticals Ltd has executed a definitive mandate for third-party sourcing and procurement services aggregating ~¥517 crore
- The mandate is a fee-based sourcing & procurement of multiple finished-dosage SKUs (Ex-Works model)
- The estimated service income revenue stream is ~%25.85 crore to be recognized over FY 2025-26
- The execution is on a call-off basis
- The mandate enhances Welcure’s fee-based portfolio without incremental balance-sheet exposure